NovaBridge Reinforces Positive Clinical Data, Outlines Phase 3 Plans for Key Cancer Drug, Appoints New CFO
summarizeSummary
NovaBridge Biosciences provided a comprehensive business update alongside its full-year 2025 financial results (which were not detailed in the article). The update highlighted positive Phase 1b data for givastomig in gastric cancer and Phase 2a data for VIS-101 in wet AMD, reiterating previously announced results. Crucially, the company confirmed potential FDA Accelerated Approval eligibility for givastomig and outlined upcoming milestones, including initiating a Phase 3 study for givastomig by year-end 2026 and Phase 2b/3 programs for VIS-101 in H2 2026 and 2027, respectively. Additionally, NovaBridge announced new executive appointments, including a Vice-Chairman and CFO, and expanded its Board of Directors. For a small-cap biotech, this update provides significant positive reinforcement of its lead pipeline assets' clinical progress and a clear, accelerated path to potential commercialization, particularly with the FDA's Accelerated Approval pathway for givastomig. The strengthening of the executive team and board also enhances confidence in the company's ability to execute on its strategic goals and upcoming milestones. Investors will be closely watching for the initiation of the Phase 3 study for givastomig by YE 2026 and the Phase 2b program for VIS-101 in H2 2026, as well as further clinical data presentations.
At the time of this announcement, NBP was trading at $2.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $279M. The 52-week trading range was $0.60 to $6.79. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.